Adding Pembrolizumab to Docetaxel Does Not Significantly Improve Outcomes in Patients with Previously Treated mCRPC By Ogkologos - April 9, 2025 611 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-921 study Source RELATED ARTICLESMORE FROM AUTHOR Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up PAXG Significantly Improves EFS Compared with mFOLFIRINOX in Patients with Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma EMA Recommends Extension of Therapeutic Indications for Retifanlimab MOST POPULAR Low Incidence of Local Recurrence When Omitting Radiotherapy after Breast-Conserving Surgery... August 22, 2023 FDA Grants Accelerated Approval to Lurbinectedin for Metastatic SCLC June 19, 2020 Woman Celebrates Beating Cancer By Creating Christmas Tree Mannequins With A... December 6, 2019 FDA Approves Sodium Thiosulfate to Reduce the Risk of Ototoxicity Associated... October 13, 2022 Load more HOT NEWS Man Who Lost His Leg Teaches Martial Arts To Orphans Of... The path to least resistance: How our researchers are outsmarting cancer’s... FDA Approves Toripalimab-tpzi for Nasopharyngeal Carcinoma HRQoL Data Support the Benefit of Adding Pembrolizumab to Chemotherapy in...
